Valneva (NASDAQ:VALN) Shares Gap Down – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $5.95, but opened at $5.60. Valneva shares last traded at $5.60, with a volume of 5,504 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a report on Wednesday, April 22nd. Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday. Finally, Guggenheim set a $11.00 target price on Valneva in a research note on Thursday, April 16th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $11.98.

Valneva Stock Performance

The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14. The company has a market cap of $527.59 million, a PE ratio of -2.97 and a beta of 1.75. The business’s 50-day moving average is $6.02 and its 200 day moving average is $8.35.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The company had revenue of $35.77 million for the quarter. On average, equities research analysts predict that Valneva SE Sponsored ADR will post -1 EPS for the current fiscal year.

Institutional Trading of Valneva

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the third quarter valued at approximately $124,000. XTX Topco Ltd purchased a new position in shares of Valneva in the fourth quarter worth $94,000. Marex Group plc bought a new stake in Valneva during the 2nd quarter valued at $64,000. China Universal Asset Management Co. Ltd. bought a new stake in Valneva during the 4th quarter valued at $44,000. Finally, VSM Wealth Advisory LLC boosted its position in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the period. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.